Preanesthesia, Anesthesia, Analgesia, and Euthanasia Paul Flecknell, MA, Vetmb, Phd, DECLAM, DLAS, DECVA, (Hon) DACLAM, (Hon) Frcvsa, Jennifer L.S

Total Page:16

File Type:pdf, Size:1020Kb

Preanesthesia, Anesthesia, Analgesia, and Euthanasia Paul Flecknell, MA, Vetmb, Phd, DECLAM, DLAS, DECVA, (Hon) DACLAM, (Hon) Frcvsa, Jennifer L.S CHAPTER 24 Preanesthesia, Anesthesia, Analgesia, and Euthanasia Paul Flecknell, MA, VetMB, PhD, DECLAM, DLAS, DECVA, (Hon) DACLAM, (Hon) FRCVSa, Jennifer L.S. Lofgren, DVM, MS, DACLAMb, Melissa C. Dyson, DVM, DACLAMb, Robert R. Marini, DVMc, M. Michael Swindle, DVMd and Ronald P. Wilson, VMD, MSe aComparative Biology Medicine, Newcastle University, Newcastle Upon Tyne, UK bUnit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA cDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts dDepartment of Comparative Medicine, Medical University of South Carolina, Charleston, SC, USA ePenn State College of Medicine, Department of Comparative Medicine, Hershey, PA, USA OUTLINE I. Introduction 1136 IV. Ferrets 1156 A. Introduction 1156 II. Rodents 1136 B. Preoperative Assessment and Preparation 1157 A. Introduction 1136 C. Intraoperative Anesthetics 1158 B. Preoperative Assessment and Preparation 1136 D. Intraoperative Monitoring and Support 1160 C. Anesthetic Agents 1137 E. Postoperative Recovery 1160 D. Intraoperative Monitoring and Support 1143 F. Acute and Chronic Analgesic Therapy 1160 E. Special Anesthetic Considerations 1144 G. Special Anesthetic Considerations 1161 F. Analgesic Therapy 1145 G. Species Considerations 1147 V. Swine 1162 H. Euthanasia 1148 A. Introduction 1162 B. Preoperative Assessment and Preparation 1162 III. Rabbits 1149 C. Intraoperative Anesthesia 1163 A. Introduction 1149 D. Intraoperative Monitoring and Support 1166 B. Preoperative Assessment and Preparation 1149 E. Special Anesthetic Considerations 1166 C. Intraoperative Anesthesia 1150 F. Postoperative Recovery 1167 D. Intraoperative Monitoring and Support 1154 G. Acute and Chronic Analgesic Therapy 1167 E. Special Anesthetic Considerations 1154 H. Euthanasia 1168 F. Acute and Chronic Analgesic Therapy 1155 Laboratory Animal Medicine, Third Edition DOI: http://dx.doi.org/10.1016/B978-0-12-409527-4.00024-9 1135 © 20122015 Elsevier Inc. All rights reserved. 1136 24. PREANESTHESIA, ANESTHESIA, ANALGESIA, AND EUTHANASIA VI. Small Ruminants 1168 C. Intraoperative Anesthesia 1182 A. Introduction 1168 D. Intraoperative Monitoring and Support 1184 B. Preoperative Evaluation and Preparation 1169 E. Special Anesthesia Considerations 1185 C. Postoperative Recovery and Pain Management 1178 F. Postoperative Recovery 1186 D. Euthanasia 1180 G. Euthanasia 1187 VII. Nonhuman Primates 1180 References 1187 A. Introduction 1180 B. Preoperative Assessment and Preparation 1180 I. INTRODUCTION analgesia for rodents are rapidly evolving. The reader is urged to consult laboratory animal anesthesia texts The purpose of this chapter is to provide practical (Gaertner et al., 2008; Flecknell, 2009) and journals for advice for administering anesthetics, analgesics, and more complete and timely information. euthanasia agents to the most commonly used labora- tory animal species. It is not meant to be an exhaustive review of all anesthetic and analgesic protocols used in B. Preoperative Assessment and Preparation these species. More detailed information is available in 1. Preanesthetic Evaluation both specialist laboratory animal anesthesia texts, (e.g., No anesthetic regimen is universally safe or appro- Fish, 2008; Kohn et al., 1997; Flecknell, 2009), and general priate. Anesthetic protocols that are satisfactory for veterinary anesthesia texts (e.g., Tranquilli et al., 2007). healthy animals can severely compromise or be fatal The most commonly used rodent species, rabbits, to unhealthy ones. A vigilant rodent health surveil- ferrets, pigs, small ruminants, and nonhuman primates lance program is the first line of defense but cannot be were selected for inclusion in this chapter. These species expected to detect alterations in husbandry or experi- encompass the overwhelming majority of laboratory ani- mental manipulations that may affect anesthesia out- mals that are currently utilized. References for in-depth comes. Preanesthetic considerations should include an discussion of anesthetic and analgesic protocols for each assessment of appearance, behavior, and bodyweight species are included within its particular section. for evidence of abnormality as well as for establishing doses for injectable agents. The history of the group of II. RODENTS animals should be examined to identify experimental, housing, and strain-specific features that might affect A. Introduction choice of anesthesic agents and techniques. In addi- tion, sex, age, and specific procedures may be expected Rodents, especially rats and mice, are the most to alter the effects of anesthesia, often to a surprising numerous and arguably the most important group of degree. A summary of anesthetic and analgesic varia- animals used in research. Among the factors that dif- tions among mice and rat stocks and strains is available ferentiate anesthetic techniques used in rodents from in the chapter on Laboratory Rodents in the second edi- those more commonly employed in larger species are tion of the text Anesthesia and Analgesia in Laboratory the small size of the animals, the perceived and often Animals (Gaertner et al., 2008). Unless the anesthetic real difficulties of vascular and airway access, and the regimen is known to be safe and effective in the animals frequent need to anesthetize large numbers of animals to be used, a pilot study should be conducted to assess in a relatively short time. Trends that have combined and verify the effects of the proposed anesthetic and to increase attention on the safe and appropriate anes- analgesic protocol (Flecknell, 2009). In all cases, it is thetic and analgesic delivery and monitoring for rodents important to allow adequate time for newly arrived ani- include: humane concerns; scientific recognition of the mals to become acclimated to changes in housing, diet, effects of pain, anesthesia, and analgesia on experimen- and husbandry conditions and to recover from shipping tal design; and the expense of generation or purchase stress. An acclimation period of at least 24–72 h is rec- of genetically altered rodents. This section will briefly ommended for rodents (Capdevila et al., 2007; Obernier discuss common anesthetic techniques for mice and rats, and Baldwin, 2006). Fasting is not usually necessary or with comments on hamsters, gerbils, and guinea pigs. recommended before anesthesia and surgery in rodents Drugs, techniques, and approaches to anesthesia and (Gaertner et al., 2008). LABORATORY ANIMAL MEDICINE II. RODENTS 1137 2. Choice of Anesthetic Techniques TABLE 24.1 Selected Anesthetic and Analgesic Doses for Micea All anesthetics have undesirable properties, so a pri- Drug Dose Route Duration mary goal must be to select an anesthetic technique that has the least adverse effect on the animal and on the ANESTHESTICS research. Thus, the goals of the research and the limita- Barbiturates tions this places on selection of the anesthetic agents must Pentobarbital 40–50 mg/kg IP 20–40 min be taken into account in formulating an anesthetic pro- tocol. For example, when prolonged stable anesthesia is EMTU (inactin) 80–mg/kg IP 60–240 min required, the choice might favor an inhalation or continu- Dissociative agents and combinations ous infusion method to avoid the variations that tend to occur with repeated bolus administration of drugs. A pro- Ketamine+ 100 mg/kg IP 20–30 min longed recovery period can further stress the animal and acepromazine 5 mg/kg the resources of the facility, favoring selection of agents Ketamine+ 50–75 mg/kg IP 20–30 min that have rapid recovery characteristics or agents that can medetomidine 1–10 mg/kg easily be reversed, such as α2-agonists, benzodiazepines, and some opioids. Finally, some techniques that meet all Ketamine+ 80–100 mg/kg IP 20–30 min of the preceding criteria may be too technically demand- xylazine 5–10 mg/kg ing or simply too expensive for the proposed research. Ketamine+ 80–100 mg/kg IP 30–40 min Inhalation anesthesia with modern agents requires the Xylazine+ 5–10 mg/kg proper equipment and training. Precise intravenous infu- sion methods may require an infusion pump, as well as acepromazine 3 mg/kg vascular access and experience with the technique. In Neuroleptanesthetics many cases, only brief anesthesia may be needed, such as procedures that may not be extremely painful but require Fentanyl-fluanisone (hypnorm) adequate restraint for the safety of the animal and the b operator (e.g., bleeding, injections, or sampling of small +midazolam 10.0 ml/kg IP 30–40 min amounts of tissue). Brief exposure to an inhalation agent Fentanyl-fluanisone 0.4 ml/kg is often selected to meet these needs. (hypnorm) In summary, selection of a suitable anesthetic tech- +diazepam 5 mg/kg IP 30–40 min nique must include professional and humane consid- Inhalant agents erations, scientific requirements and restrictions, and recognition of technical and personnel limitations. Isoflurane 1–4%, to effect Inhalant 3. Preanesthetic Medications Other agents Preanesthetic drugs are not commonly used in Propofol 12–26 mg/kg IV 5–10 min rodents. However, the advantages of sedation, analge- Tribromoethanol 125–300 mg/kg IP 15–45 min sia, and reduced doses of the general anesthetic agent or agents apply equally well to rodents. The principal ANALGESICS disadvantage of using a preanesthetic agent in rodents Buprenorphine 0.05–0.1 mg/kg SC, IP 6–12 h is the need to restrain and thus stress the animals twice Butorphanol 1–5 mg/kg SC, IP 4 h rather than once for the induction of anesthesia.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Alfadolone Acetate (BANM, Rinnm) 362: 1749–57
    1780 General Anaesthetics blood, then to the brain; recovery is a function of the zolam, and other anaesthetics such as etomidate, propofol, ful if the patient’s cooperation is required, as conscious- removal of the anaesthetic from the brain. With inject- or ketamine. Small doses of short-acting opioids, for ex- ness soon returns once the nitrous oxide is stopped. The able anaesthetics their activity is similarly dependent ample alfentanil, fentanyl, or remifentanil, given before or neuroleptic most commonly employed was droperidol and on their ability to penetrate the blood/brain barrier and at induction allow the use of smaller induction doses of it was usually used with fentanyl although other opioids recovery in turn is governed by their redistribution and some drugs used for anaesthesia, and this technique is par- have also been used. These procedures have since evolved ticularly suitable for poor-risk patients. into conscious sedation and monitored anaesthetic care excretion. The potency of inhalational anaesthetics is After induction, muscle relaxation with a rapidly acting techniques employing newer drugs. often expressed in terms of minimum alveolar concen- depolarising neuromuscular blocker such as suxamethoni- Ketamine used alone can produce a state of dissociative trations, known as MAC values. The MAC of an um aids intubation of the patient. Longer acting, compet- anaesthesia similar to that of neuroleptanalgesia in which anaesthetic is the concentration at 1 atmosphere that itive neuromuscular blockers may then be given to allow the patient may appear to be awake but is unconscious. will produce immobility in 50% of subjects exposed to procedures such as abdominal surgery to be carried out un- Marked analgesia and amnesia are produced, but there a noxious stimulus.
    [Show full text]
  • G Genito Urinary System and Sex Hormones
    WHO/EMP/RHT/TSN/2018.2 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Learning clinical pharmacology with the use of INNs and their stems. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.2). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Effects of Alfaxalone Or Propofol on Giant-Breed Dog Neonates Viability
    animals Article Effects of Alfaxalone or Propofol on Giant-Breed Dog Neonates Viability During Elective Caesarean Sections Monica Melandri 1, Salvatore Alonge 1,* , Tanja Peric 2, Barbara Bolis 3 and Maria C Veronesi 3 1 Società Veterinaria “Il Melograno” Srl, 21018 Sesto Calende, Varese, Italy; [email protected] 2 Department of Agricultural, Food, Environmental and Animal Sciences, University of Udine, 33100 Udine, Italy; [email protected] 3 Department of Veterinary Medicine, Università degli Studi di Milano, 20100 Milan, Italy; [email protected] (B.B.); [email protected] (M.C.V.) * Correspondence: [email protected]; Tel.: +39-392-805-8524 Received: 20 September 2019; Accepted: 7 November 2019; Published: 13 November 2019 Simple Summary: Nowadays, thanks to the increased awareness of owners and breeders and to the most recent techniques available to veterinarians, the management of parturition, especially of C-sections, has become a topic of greater importance. Anesthesia is crucial and must be targeted to both the mother and neonates. The present study aimed to evaluate the effect of the induction agent alfaxalone on the vitality of puppies born from elective C-section, in comparison to propofol. After inducing general anesthesia for elective C-section, puppies from the mothers induced with alfaxalone had higher 5-min Apgar scores than those induced with propofol. The concentration of cortisol in fetal fluids collected at birth is neither influenced by the anesthetic protocol used, nor does it differ between amniotic and allantoic fluids. Nevertheless, the cortisol concentration in fetal fluids affects the relationship between anesthesia and the Apgar score: the present study highlights a significant relationship between the anesthetic protocol used and Apgar score in puppies, and fetal fluids cortisol concentration acts as a covariate of this relationship.
    [Show full text]
  • Evaluation the Clinical Effects of Neuroleptanalgesia During
    AL-Qadisiya Journal of Vet. Med. Sci. Vol. 14 No. 1 2015 Evaluation the clinical effects of neuroleptanalgesia (Remifentanil-Acepromazine, Remifentanil-Xylazine, and Remifentanil-Midazolam) during intubation and some minor surgical operations in dogs Samir Aoda Jaffar Ayad Abed-Al-Jabbar Amin Coll. of Vet. Med. / Univ. of Baghdad email: [email protected] (Received 9 January 2014, Accepted 21 April 2014) Abstract The present study intends to evaluate and compare the clinical effects of neuroleptanalgesia induced by using one of the sedative-opioid or tranquilizer-opioid (neuroleptanalgesia) combinations during intubation and some minor surgical operations in dogs. Twenty seven apparently healthy dogs weighing from (15-20 kg) and aged (2-4 years) were divided into three groups, all animals were premedicated with atropine (0.03 mg/kg BW) IM, after 15 minutes neuroleptanalgesia induced as following: Group 1, giving Acepromazine 1mg/kg BW IM and remifentanil 0.5 μg/kg BW IV. Group 2, giving Xylazine 2mg/kg BW IM and remifentanil 0.5 μg/kg BW IV. Group 3, giving Midazolam 0.2mg/kg BW IM and remifentanil 0.5 μg/kg BW IV), in 10 minutes interval respectively in all groups. The following parameters were used for evaluation during the state of (neuroleptanalgesia), eye reflexes, duration and degree of surgical analgesia, degree of sedation, muscle relaxation, respiratory rate, rectal body temperature, and heart rate and rhythm. The results of the study was characterized by good sedation with minor change in heart and respiratory rates and body temperature with excellent analgesia and muscle relaxation quite enough to performed intubation, docking and declawing in groups one and two and less in quality in third group.
    [Show full text]
  • Restraint and Anesthesia of Uncommon Veterinary Patients Bruce H
    Volume 47 | Issue 1 Article 9 1985 Restraint and Anesthesia of Uncommon Veterinary Patients Bruce H. Garver Iowa State University Larry L. Jackson Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/iowastate_veterinarian Part of the Anesthesia and Analgesia Commons, and the Veterinary Medicine Commons Recommended Citation Garver, Bruce H. and Jackson, Larry L. (1985) "Restraint and Anesthesia of Uncommon Veterinary Patients," Iowa State University Veterinarian: Vol. 47 : Iss. 1 , Article 9. Available at: https://lib.dr.iastate.edu/iowastate_veterinarian/vol47/iss1/9 This Article is brought to you for free and open access by the Journals at Iowa State University Digital Repository. It has been accepted for inclusion in Iowa State University Veterinarian by an authorized editor of Iowa State University Digital Repository. For more information, please contact [email protected]. Restraint and Anesthesia of Uncommon Veterinary Patients Bruce H. Garver, BS* Larry L. Jackson, DVM, MS, DACVA** Inttbduction Anesthesia The presentation of small mammals, birds, The variations in anatomical features, size, and reptiles as patients can create consider­ percent body-fat, metabolism, drug sensitivi­ able problems for the veterinarian. Oftenti­ ties, and pre-anesthetic health of the animal mes the veterinarian feels uncomfortable han­ must be considered when anesthesia is to be dling uncommon pets for fear of injury to the administered. Ambient temperature is an im­ pet or clinic staff. This often sends the veteri­ portant consideration. Many anesthetics alter narian searching through textbooks hoping to the animals thermoregulatory mechanism, find a short and concise section dealing with therefore, it is necessary to keep anesthetized the patient at hand.
    [Show full text]
  • 24Hrs Patent Application Publication May 21 , 2020 Sheet 1 of 6 US 2020/0155522 A1
    US 20200155522A1 IN (19 ) United States (12 ) Patent Application Publication ( 10 ) Pub . No.: US 2020/0155522 A1 Osten et al. (43 ) Pub . Date : May 21 , 2020 (54 ) GABOXADOL FOR REDUCING RISK OF Publication Classification SUICIDE AND RAPID RELIEF OF (51 ) Int. Ci. DEPRESSION A61K 31/437 (2006.01 ) A61K 31/135 (2006.01 ) ( 71) Applicant: Certego Therapeutics , Farmingdale , A61P 25/24 ( 2006.01 ) NY (US ) (52 ) U.S. CI. (72 ) Inventors: Pavel Osten , Brooklyn , NY (US ) ; CPC A61K 31/437 (2013.01 ) ; A61P 25/24 Kristin Baldwin , San Diego , CA (US ) ( 2018.01 ) ; A61K 31/135 ( 2013.01 ) (73 ) Assignee : Certego Therapeutics, Farmingdale , ( 57 ) ABSTRACT NY (US ) Methods and compositions are disclosed for rapidly reduc (21 ) Appl. No.: 16 /691,049 ing the risk of suicide in patients suffering from acute suicidality and rapidly relieving mood symptoms in major ( 22 ) Filed : Nov. 21 , 2019 depression and treatment - resistant depression using a novel therapeutic regimen comprising a single or intermittent Related U.S. Application Data administration of a high dose of gaboxadol, or a pharma (60 ) Provisional application No.62 / 770,287 , filed on Nov. ceutically acceptable salt thereof, to the subject n need 21 , 2018 . thereof. 220 I ther 24hrs Patent Application Publication May 21 , 2020 Sheet 1 of 6 US 2020/0155522 A1 FIGURE1:METHODFORWHOLE-BRAINPHARMACOMAPSREPRESENTINGDRUGEVOKED ACTIVATIONINTHEMOUSE. Patent Application Publication May 21 , 2020 Sheet 2 of 6 US 2020/0155522 A1 FIGURE 2 : KETAMINE DOSE - CURVE PHARMACOMAPS , Ketamine
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • The Practice of Veterinary Anesthesia: Small Animals, Birds, Fish and Reptiles This Page Intentionally Left Blank PVA Guts Layout 1 10/14/13 8:35 AM Page Iii
    PVA_Guts_Layout 1 10/14/13 8:35 AM Page i The Practice of Veterinary Anesthesia: Small Animals, Birds, Fish and Reptiles This page intentionally left blank PVA_Guts_Layout 1 10/14/13 8:35 AM Page iii The Practice of Veterinary Anesthesia: Small Animals, Birds, Fish and Reptiles Donald C. Sawyer, DVM, PhD, DACVA Teton NewMedia Teton NewMedia 90 East Simpson, Suite 110 Jackson, WY 83001 © 2008 by Tenton NewMedia Exclusive worldwide distribution by CRC Press an imprint of Taylor & Francis Group, an Informa business Version Date: 20140128 International Standard Book Number-13: 978-1-4822-4129-7 (eBook - PDF) This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not necessarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional’s own judgement, their knowledge of the patient’s medical history, relevant manufacturer’s instructions and the appropriate best practice guide- lines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the drug companies’ printed instructions, and their websites, before administering any of the drugs recommended in this book.
    [Show full text]
  • Ep 2277556 A1
    (19) & (11) EP 2 277 556 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.01.2011 Bulletin 2011/04 A61L 15/58 (2006.01) A61L 15/00 (2006.01) A61L 24/00 (2006.01) (21) Application number: 10178994.9 (22) Date of filing: 01.05.2002 (84) Designated Contracting States: • Cleary, Gary W. AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Los Altos, CA 94022-4481 (US) MC NL PT SE TR • Kulichikhin, Valery G. Moscow 119021 (RU) (30) Priority: 01.05.2001 US 288024 P • Bairamov, Danir F. Moscow 117292 (RU) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (74) Representative: Mallalieu, Catherine Louise 02746327.2 / 1 390 084 D Young & Co LLP 120 Holborn (71) Applicants: London EC1N 2DY (GB) • A. V. Topchiev Institute of Petrochemical Synthesis Remarks: Moscow, 117912 (RU) This application was filed on 23-09-2010 as a • Corium International divisional application to the application mentioned Redwood City, CA 94063 (US) under INID code 62. (72) Inventors: • Feldstein, Mikhail M. Moscow 117912 (RU) (54) Two-phase, water-absorbent bioadhesive composition (57) An adhesive composition is provided that con- drogen bonding, ionic bonding, and/or covalent bonding. tains both a hydrophobic phase and a hydrophilic phase, The composition is useful as a bioadhesive, for affixing wherein the hydrophobic phase is composed of a drug delivery systems, wound dressings, bandages, crosslinked hydrophobic polymer composition and the cushions, or the like to a body surface such as skin or hydrophilic phase is a water-absorbent blend of a hy- mucosal tissue.
    [Show full text]
  • ATIVAN (Lorazepam) Injection, USP)
    ATIVAN (lorazepam) injection, USP) For intravenous and intramuscular use NOT FOR USE IN NEONATES CONTAINS BENZYL ALCOHOL WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Monitor patients for respiratory depression and sedation (see WARNINGS and PRECAUTIONS, Drug Interactions). DESCRIPTION Lorazepam, a benzodiazepine with antianxiety, sedative, and anticonvulsant effects, is intended for the intramuscular or intravenous routes of administration. It has the chemical formula: 7-chloro-5(2­ chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1, 4-benzodiazepin-2-one. The molecular weight is 321.16, and the C.A.S. No. is [846-49-1]. The structural formula is: Lorazepam is a nearly white powder almost insoluble in water. Each mL of sterile injection contains either 2.0 or 4.0 mg of lorazepam, 0.18 mL polyethylene glycol 400 in propylene glycol with 2.0% benzyl alcohol as preservative. CLINICAL PHARMACOLOGY Lorazepam interacts with the γ-aminobutyric acid (GABA)-benzodiazepine receptor complex, which is widespread in the brain of humans as well as other species. This interaction is presumed to be responsible for lorazepam’s mechanism of action. Lorazepam exhibits relatively high and specific affinity for its recognition site but does not displace GABA. Attachment to the specific binding site enhances the affinity of GABA for its receptor site on the same receptor complex. The pharmacodynamic consequences of benzodiazepine agonist actions include antianxiety effects, sedation, and reduction of seizure activity. The intensity of action is directly related to the degree of benzodiazepine receptor occupancy.
    [Show full text]